PHARMANIAGA BHD
KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.305
Today's Change
0.00 (0.00%)
Day's Change
0.30 - 0.31
Trading Volume
2,750,600
Financial
Market Cap
440 Million
NOSH
1,441 Million
Latest Quarter
31-Dec-2023 [#4]
Announcement Date
29-Feb-2024
Next Quarter
31-Mar-2024
Est. Ann. Date
18-May-2024
Est. Ann. Due Date
30-May-2024
QoQ | YoY
33.68% | 94.92%
Revenue | NP to SH
3,404,481.000 | -77,451.000
RPS | P/RPS
236.22 Cent | 0.13
EPS | P/E | EY
-5.37 Cent | -5.68 | -17.62%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.20 | 0.00
QoQ | YoY
88.76% | 87.25%
NP Margin | ROE
-2.23% | 0.00%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Latest Audited Result
31-Dec-2023
Announcement Date
29-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
29-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Revenue | NP to SH
3,404,481.000 | -77,452.000
RPS | P/RPS
236.22 Cent | 0.13
EPS | P/E | EY
-5.37 Cent | -5.68 | -17.62%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.20 | 0.00
YoY
87.25%
NP Margin | ROE
-2.23% | 0.00%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Revenue | NP to SH
3,404,481.000 | -77,452.000
RPS | P/RPS
236.22 Cent | 0.13
EPS | P/E | EY
-5.37 Cent | -5.68 | -17.62%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-29.86% | 87.25%
NP Margin | ROE
-2.23% | 0.00%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Show?
| Last 10 FY Result | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,404,481 | 3,404,481 | 3,404,481 | 3,510,677 | 4,815,015 | 2,725,071 | 2,820,530 | 2,384,956 | 2,323,960 | 2,189,022 | 2,189,312 | 2,122,933 | 5.38% | |
| PBT | -62,823 | -62,823 | -62,823 | -580,846 | 277,075 | 35,793 | -191,865 | 70,220 | 73,064 | 72,017 | 112,722 | 125,580 | - | |
| Tax | -13,213 | -13,213 | -13,213 | -24,204 | -104,870 | -9,524 | 42,418 | -26,990 | -17,977 | -26,158 | -28,138 | -31,355 | -9.15% | |
| NP | -76,036 | -76,036 | -76,036 | -605,050 | 172,205 | 26,269 | -149,447 | 43,230 | 55,087 | 45,859 | 84,584 | 94,225 | - | |
| - | ||||||||||||||
| NP to SH | -77,452 | -77,451 | -77,452 | -607,317 | 172,150 | 27,489 | -149,219 | 42,468 | 53,823 | 45,599 | 84,044 | 93,844 | - | |
| - | ||||||||||||||
| Tax Rate | - | - | - | - | 37.85% | 26.61% | - | 38.44% | 24.60% | 36.32% | 24.96% | 24.97% | - | |
| Total Cost | 3,480,517 | 3,480,517 | 3,480,517 | 4,115,727 | 4,642,810 | 2,698,802 | 2,969,977 | 2,341,726 | 2,268,873 | 2,143,163 | 2,104,728 | 2,028,708 | 6.17% | |
| - | ||||||||||||||
| Net Worth | -281,734 | -281,734 | -281,734 | -248,894 | 450,411 | 337,298 | 336,573 | 509,862 | 526,888 | 531,169 | 529,482 | 525,526 | - | |
| Equity | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Worth | -281,734 | -281,734 | -281,734 | -248,894 | 450,411 | 337,298 | 336,573 | 509,862 | 526,888 | 531,169 | 529,482 | 525,526 | - | |
| NOSH | 1,441,229 | 1,441,229 | 1,441,229 | 1,309,126 | 1,309,126 | 261,705 | 261,229 | 260,505 | 259,821 | 259,377 | 258,915 | 258,880 | 21.00% | |
| Ratio Analysis | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NP Margin | -2.23% | -2.23% | -2.23% | -17.23% | 3.58% | 0.96% | -5.30% | 1.81% | 2.37% | 2.09% | 3.86% | 4.44% | - | |
| ROE | 0.00% | 0.00% | 0.00% | 0.00% | 38.22% | 8.15% | -44.33% | 8.33% | 10.22% | 8.58% | 15.87% | 17.86% | - | |
| Per Share | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPS | 248.93 | 248.93 | 248.93 | 268.00 | 367.74 | 1,042.20 | 1,081.04 | 916.82 | 895.38 | 844.83 | 845.57 | 820.05 | -12.39% | |
| EPS | -5.66 | -5.66 | -5.66 | -46.36 | 13.15 | 10.51 | -57.19 | 16.33 | 20.74 | 17.60 | 32.46 | 36.25 | - | |
| DPS | 0.00 | 0.00 | 0.00 | 1.90 | 9.30 | 11.00 | 8.50 | 16.00 | 19.00 | 16.00 | 30.00 | 28.00 | - | |
| NAPS | -0.206 | -0.206 | -0.206 | -0.19 | 0.344 | 1.29 | 1.29 | 1.96 | 2.03 | 2.05 | 2.045 | 2.03 | - | |
| Adjusted Per Share Value based on latest NOSH - 1,441,229 | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RPS | 236.22 | 236.22 | 236.22 | 243.59 | 334.09 | 189.08 | 195.70 | 165.48 | 161.25 | 151.89 | 151.91 | 147.30 | 5.38% | |
| EPS | -5.37 | -5.37 | -5.37 | -42.14 | 11.94 | 1.91 | -10.35 | 2.95 | 3.73 | 3.16 | 5.83 | 6.51 | - | |
| DPS | 0.00 | 0.00 | 0.00 | 1.73 | 8.45 | 2.00 | 1.54 | 2.89 | 3.42 | 2.88 | 5.39 | 5.03 | - | |
| NAPS | -0.1955 | -0.1955 | -0.1955 | -0.1727 | 0.3125 | 0.234 | 0.2335 | 0.3538 | 0.3656 | 0.3686 | 0.3674 | 0.3646 | - | |
| Price Multiplier on Financial Quarter End Date | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date | 29/12/23 | 29/12/23 | 29/12/23 | 30/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 29/12/17 | 30/12/16 | 31/12/15 | 31/12/14 | - | |
| Price | 0.385 | 0.385 | 0.385 | 0.545 | 0.74 | 5.00 | 2.06 | 2.78 | 4.60 | 5.30 | 6.36 | 4.58 | - | |
| P/RPS | 0.15 | 0.15 | 0.15 | 0.20 | 0.20 | 0.48 | 0.19 | 0.30 | 0.51 | 0.63 | 0.75 | 0.56 | -13.60% | |
| P/EPS | -6.80 | -6.80 | -6.80 | -1.18 | 5.63 | 47.56 | -3.60 | 17.03 | 22.18 | 30.12 | 19.59 | 12.63 | - | |
| EY | -14.71 | -14.71 | -14.71 | -85.07 | 17.77 | 2.10 | -27.76 | 5.87 | 4.51 | 3.32 | 5.10 | 7.91 | - | |
| DY | 0.00 | 0.00 | 0.00 | 3.49 | 12.57 | 2.20 | 4.13 | 5.76 | 4.13 | 3.02 | 4.72 | 6.11 | - | |
| P/NAPS | 0.00 | 0.00 | 0.00 | 0.00 | 2.15 | 3.88 | 1.60 | 1.42 | 2.27 | 2.59 | 3.11 | 2.26 | - | |
| Price Multiplier on Announcement Date | ||||||||||||||
| AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date | 29/02/24 | 29/02/24 | 29/02/24 | 27/02/23 | 17/02/22 | 17/03/21 | 20/02/20 | 21/02/19 | 27/02/18 | 21/02/17 | 15/02/16 | 23/02/15 | - | |
| Price | 0.37 | 0.37 | 0.37 | 0.44 | 0.76 | 3.49 | 2.04 | 2.76 | 4.04 | 5.12 | 6.19 | 5.28 | - | |
| P/RPS | 0.15 | 0.15 | 0.15 | 0.16 | 0.21 | 0.33 | 0.19 | 0.30 | 0.45 | 0.61 | 0.73 | 0.64 | -14.87% | |
| P/EPS | -6.53 | -6.53 | -6.53 | -0.95 | 5.78 | 33.20 | -3.57 | 16.91 | 19.48 | 29.09 | 19.07 | 14.57 | - | |
| EY | -15.31 | -15.31 | -15.31 | -105.37 | 17.30 | 3.01 | -28.04 | 5.92 | 5.13 | 3.44 | 5.24 | 6.87 | - | |
| DY | 0.00 | 0.00 | 0.00 | 4.32 | 12.24 | 3.15 | 4.17 | 5.80 | 4.70 | 3.13 | 4.85 | 5.30 | - | |
| P/NAPS | 0.00 | 0.00 | 0.00 | 0.00 | 2.21 | 2.71 | 1.58 | 1.41 | 1.99 | 2.50 | 3.03 | 2.60 | - | |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
Discussions
6 people like this. Showing 50 of 14,051 comments
High Court sentenced Siddek to 2 whippings....nobody getting whipped here???
2023-11-10 12:17
Bankers knocking on doors yet????? Ah long already splash red paints????
2023-11-21 07:45
Angkatan Tentera bagi tau......Selamatkan diri????
AmirIffaan
Pharma ada angkatan tentera, tak takut ah long dan bankers 😂
2023-11-30 03:44
Minum, makan besar, jamuan semua dia orang........now shareholders pay the Bills......hahahaha
2023-11-30 09:38
Jilaka Ex-CEO and Ex-director tak kena tangkap or investigate ..... All the happy for management , all the painful shareholders.
2023-11-30 13:33
Spineless promoter.......
Posted by AmirIffaan > 6 days ago | Report Abuse
Pharma ada angkatan tentera, tak takut ah long dan bankers 😂
2023-12-01 11:49
Spineless promoter today......
Posted by AmirIffaan > 6 minutes ago | Report Abuse
2x sen datang lagi?
2023-12-01 11:50
So freaking surprised the day after announcements, price still can be at 36.5c..!!!! sucker suiyee bilis refused to sell, now 33c is so happy for them.........more to go......
2023-12-02 08:56
To save the company one way is to privatise it by Boustead
Pharma contract with the gov has been renewed till 2027 . So it’s a golden goose
2023-12-04 14:47
You think LTAT people don't know Maths????..........figures don't add up.
2023-12-04 14:48
Shareholders will have to decide either sell to Boustead/LTAT or the company go bust. (Sorry to say will have to accept whatever offer it is)
2023-12-04 14:51
No way LTAT wants to Privatise and fork out Billions for Debts and MBO........
2023-12-04 14:56
Price 40.5
Resistance 42.5 cents
Doubt the bank will be right for 31 cents.
If pass the resistance a while,
Tp 55-60 cents.
But there risk of capital consolidate like aax style to wipe out it borrowing.pharma borrowing 800 million ++and negatives shareholder fund of over 200 over million to need to be settle
6/1/24 2.30pm
2024-01-06 14:24
Wah it really got capital consolidate after wht i say 6/1/24.
https://theedgemalaysia.com/node/702178
24/2/24 3.01pm
Price 40.5
Resistance 42.5 cents
Doubt the bank will be right for 31 cents.
If pass the resistance a while,
Tp 55-60 cents.
But there risk of capital consolidate like aax style to wipe out it borrowing.pharma borrowing 800 million ++and negatives shareholder fund of over 200 over million to need to be settle
6/1/24 2.30pm
2 months ago
Old People out New people in hari hari play like flip flog jump, At the end what purpose and what can be improve for the revenue or share price although what kind high education of leaderships . Still follow the bad style at the end nothing gain, hopeless to all shareholder .
1 month ago
Duopharma on Tuesday announced that it had accepted 11 letters of offer from Pharmaniaga Logistics Sdn Bhd for the supply of 86 pharmaceutical and/or non-pharmaceutical products worth RM578.1mil to offices and facilities operated and controlled by the government.
https://www.thestar.com.my/business/business-news/2024/05/03/duopharmas-new-rm578mil-contracts-a-positive#:~:text=Duopharma%20on%20Tuesday%20announced%20that,and%20controlled%20by%20the%20government.
2 days ago
Auditor casts doubt on Pharmaniaga’s ability to continue as a going concern
https://www.freemalaysiatoday.com/category/highlight/2024/05/08/auditor-casts-doubt-on-pharmaniagas-ability-to-continue/
1 day ago
Post a Comment
Featured Posts
Get Your NVDA Share by Opening a Moomoo Account*!
MQ Trading Signals
Time
Signal
Duration
Type
2024-05-10 16:00:00
EMA 5
10 Mins
SELL
2024-05-10 16:00:00
EMA 5
5 Mins
SELL
2024-05-10 15:10:00
OBV
10 Mins
BUY
2024-05-10 15:00:00
TURTLE SYSTEM 20
5 Mins
SELL
2024-05-10 14:50:00
EMA 5
10 Mins
BUY
Apps
Top Articles
1
4
5
6
RHB Investment Research Reports
Technology, Property, and Construction - Penang- Silicon Hub of ASEAN
7
Follow Kim's Stockwatch!
THIS ANOTHER GEMS READY TO SKYROCKET!!! - MAJOR DEVELOPER IN PENANG
8
博傻理论
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Runnerup
Come down 260 again , i wish ...
2023-10-04 09:55